Our findings not only help explain how BRAF-mutant melanoma survives the acute phases of MAPK inhibition, they also highlight an emerging theme of pro-invasive small GTPases that link mechanisms of tumorigenesis to drug resistance. The gene discussed is BRAF; the disease is melanoma.